• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

WellDoc Pulls In $22M To Accelerate Mobile Prescription Therapy Adoption

by HITC Staff 12/17/2015 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

WellDocDigital health technology company WellDoc today announced $22 million in Series B funding led by Samsung Ventures and Merck Global Health Innovation (GHI) Fund serving as co-lead. Other participants in the round include Adage  Capital Management, Excel Venture Management, Alexandria Venture Investments and Hudson River Capital Partners LLC. 

Welldoc plans to utilize the funding to continue commercialization and accelerate adoption of its flagship product, BlueStar, a FDA cleared mobile prescription therapy developed for adults living with type 2 diabetes and their doctors. Mobile prescription therapy fills the support gap between patients and providers during the 8700 hours that individuals are living their lives outside the healthcare system. The patient-centered product requires a prescription from a licensed healthcare provider and can be dispensed by a pharmacy and reimbursed by a health plan.

Powered by WellDoc’s proprietary Automated Expert Analytics System, BlueStar enables patients to self-manage their diabetes through real-time motivational, behavioral and educational coaching. BlueStar coordinates care by helping patients adhere to their treatment plan while also providing clinical decision support to the patient’s healthcare provider to optimize treatment decisions.

“The success of our initial commercial launch of BlueStar has provided us with valuable information that we will use to expand nationally to bring BlueStar to adults with type 2 diabetes,” said Kevin McRaith, CEO of WellDoc in a statement. “Our goal is to help improve patient self-management, which ultimately leads to better outcomes as demonstrated in our published clinical trials, as well as our commercial launch. The progress reported by those who have used BlueStar to date, and the data we have captured from that usage, motivates us to find new ways to make our product available to more people. With the financial contributions and strategic capabilities of the investors participating in our Series B, we can take WellDoc and BlueStar to the next level – evolving our business model and distribution channels.”

In a regional product demonstration primarily in the State of Maryland, 55 percent of targeted physicians prescribed BlueStar. The real-time data captured in the product aids in predictive analytics that can lead to cost avoidance and monetary savings. BlueStar users are highly satisfied with the product as demonstrated through usage and satisfaction surveys. In addition, the highest usage rates are derived from users who are over 60 years old, an important market segment.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: WellDoc

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

Pfizer Acquires Metsera for $4.9B, Expanding into Obesity and Cardiometabolic Market

Pfizer Acquires Metsera for $4.9B, Expanding into Obesity and Cardiometabolic Market

CVS Health Subsidiary Omnicare Files for Bankruptcy to Tackle Financial Challenges

CVS Health Subsidiary Omnicare Files for Bankruptcy to Tackle Financial Challenges

Sutter Health and Epic Launch "Sutter Sync" to Optimize Remote Chronic Care

Sutter Health and Epic Launch “Sutter Sync” to Optimize Remote Chronic Care

Corti Joins Coalition for Health AI to Advance Responsible and Safe AI in Healthcare

Joint Commission and CHAI Release First-Ever Guidance for Responsible AI in Healthcare

71% of Hospitals Now Use Predictive AI, But a Digital Divide Remains

71% of Hospitals Now Use Predictive AI, But a Digital Divide Remains

PHTI Report: Virtual OUD Solutions are Effective, But Don't Substantially Reduce Costs

PHTI Report: Virtual OUD Solutions are Effective, But Don’t Substantially Reduce Costs

Bayer Exits Radiology AI Market, Discontinuing Calantic and Blackford

Bayer Exits Radiology AI Market, Discontinuing Calantic and Blackford

Oracle Health Launches AI Center of Excellence for Healthcare

Oracle Health Launches AI Center of Excellence for Healthcare

Particle Health Addresses Integration to Epic Data Despite Dispute

US Court Allows Particle’s Antitrust Claims Against Epic to Proceed

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |